Time period | RI coverage (POL3) | SIA schedule showing: vaccine (day(s) of year) |
---|---|---|
Before tOPV intensification on January 1, 2015 | 0.05 or 0.1 | tOPV (0, 40); bOPV (80, 140, 240, 300) |
0.3 | tOPV (0, 40); bOPV (80, 140, 240) | |
0.6 (R0 ≤ 10) | tOPV (0); bOPV (60, 120) | |
0.6 (R0 > 10) | tOPV (0, 40); bOPV (80, 140, 240) | |
0.9 | tOPV (0) | |
0.98 (R0 ≤ 10) | No SIAs | |
0.98 (R0 > 10) | tOPV (0) | |
During tOPV intensification (January 1, 2015 to April 1, 2016) | 0.05 or 0.1 | tOPV (0, 40, 80, 300); bOPV (140, 240) |
0.3 | tOPV (0, 40, 80); bOPV (140, 240) | |
0.6 (R0 ≤ 10) | tOPV (0, 60); bOPV (120) | |
0.6 (R0 > 10) | tOPV (0, 40, 80); bOPV (140, 240) | |
0.9 | tOPV (0) | |
0.98 (R0 ≤ 10) | No SIAs | |
0.98 (R0 > 10) | tOPV (0) | |
After tOPV intensification (April 1, 2016 to OPV13 cessation) | 0.05 or 0.1 | bOPV (0, 40, 80, 140, 240, 300) |
0.3 | bOPV (0, 40, 80, 140, 240) | |
0.6 (R0 ≤ 10) | bOPV (0, 60, 120) | |
0.6 (R0 > 10) | bOPV (0, 40, 80, 140, 240) | |
0.9 | bOPV (0) | |
0.98 (R0 ≤ 10) | No SIAs | |
0.98 (R0 > 10) | bOPV (0) |